Direct-Acting Antivirals' Safety Profile in Patients with Advanced Liver Cirrhosis with Hepatitis C: A Systematic Review and Meta-Analysis
No Thumbnail Available
Date
2024-06
Journal Title
Journal ISSN
Volume Title
Publisher
Ms. M. B. Mondal
Abstract
Chronic hepatitis C with cirrhosis is treated with direct-acting antibiotics (DAAs). The aim of this study was to investigate the effect of direct-acting antibodies in the treatment of hepatitis C in cirrhosis. It also examines the proportion of drug-related problems, side effects, and mortality. The Cochrane Library and PubMed were thoroughly searched for the required literature. Fifteen articles were extracted for inclusion in this systematic review and meta-analysis. A total of 16 studies were thoroughly screened. The included studies provided a comprehensive picture of the effects of DAA therapy, spanning multiple study designs and sites Our analysis showed that good responses were observed with DAA regimens and that treatment discontinuation was low due to adverse events a stirring that. Few adverse events were reported, but all were mostly uncontrolled to prevent treatment discontinuation or death. In addition, meta-analytic studies on specific outcomes such as encephalopathy, ascites, hepatocellular carcinoma (HCC), adverse events, and death provided quantitative analysis about the safety of DAAs. Research also shows that DAAs have fewer side effects, deaths, and complications than other treatments.
Description
Keywords
Hepatitis C, direct-acting antivirals (DAAs), liver cirrhosis, systematic review, meta-analysis, safety profile, adverse events, treatment efficacy, chronic liver disease, viral eradication
Citation
Khan SM, Nazmin F, Ray R, Hachem R, Wade B, Bhinder MA, Chaudhry MB, Syed M, Khan A, Fatima E, Ullah I.. Direct-Acting Antivirals' Safety Profile in Patients with Advanced Liver Cirrhosis with Hepatitis C: A Systematic Review and Meta-Analysis. Journal of Advances in Medicine and Medical Research. 2024 Jun; 36(6): 266-281